EXPLORING THE THERAPEUTIC POTENTIAL OF SUNITINIB IN THE MANAGEMENT OF METASTATIC ALVEOLAR SOFT PART SARCOMA: A COMPREHENSIVE CASE REPORT
DOI:
https://doi.org/10.55519/JAMC-01-12653Keywords:
Alveolar soft part sarcoma, palliative intent, targeted treatmentAbstract
Background: Alveolar soft part sarcoma is a rare subtype of sarcoma. It comprises around 0.5% of all soft tissue sarcomas. It is a disease of the young, mainly affecting people less than 25 years of age. Its incidence is much higher in females than in males. In some instances, it may be associated with exposure to prior radiation and genetic syndromes such as Li Fraumeni and Retinoblastoma. It is a very slow-growing tumour. It can metastasize to the lungs, bones, or brain. It has an overall survival rate of around 56%. Case Report: We report the case of a 22-year-old female patient. She is a known case of Metastatic retroperitoneal Alveolar soft part sarcoma with lung metastasis. She was initially evaluated outside our institute for complaints of abdominal pain and a large left retroperitoneal mass, measuring 17×9×13.5 cm, extending to the left pelvis. She had a locally unresectable disease. CT scan of the Chest revealed bilateral sub-centimeter pulmonary nodules, approximately 8.6 mm in diameter. She later came to us for further management. She had complaints of abdominal pain and discomfort. Following a thorough discussion, she was counselled about the diagnosis of metastatic disease, and it was explained that the treatment would be palliative in intent. She was started on treatment with Sunitinib 37.5 mg once a day. She was also assessed for genetic syndromes. Her genetic test was negative. She has been tolerating the treatment well. Conclusion: This tumour is very rare, and data are scarce regarding its presentation and management. There is no consensus on the treatment of this disease yet, and it follows an indolent course with an increased risk of distant metastases. Targeted treatment, including novel small tyrosine kinase inhibitors in patients with metastatic disease, has shown some promising results regarding response to these therapeutically resilient soft tissue sarcomas along with improved survival.
References
1. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 2012;118(5):1387–96.
2. Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007;99(1):24–31.
3. Chang X, Li Y, Xue X, Zhou H, Hou L. The current management of alveolar soft part sarcomas. Medicine (Baltimore) 2021;100(31):e26805.
4. Xu Z, Zhang Y, Yu YH. Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: a case report. Ann Palliat Med 2021;10(1):785–92.
5. Wang B, Wang H, Wei J, Qu L, Meng L, Xin Y, et al. Alveolar soft part sarcoma of the right calf: A case report. Medicine (Baltimore) 2020;99(5):e18952.
6. Fujiwara T, Nakata E, Kunisada T, Ozaki T, Kawai A. Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study. BMC Cancer 2022;22(1):891.
7. Ogura K, Beppu Y, Chuman H, Yoshida A, Yamamoto N, Sumi M, et al. Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature. Sarcoma 2012;2012:907179.
8. Sood S, Baheti AD, Shinagare AB, Jagannathan JP, Hornick JL, Ramaiya NH, et al. Imaging features of primary and metastatic alveolar soft part sarcoma: single institute experience in 25 patients. Br J Radiol 2014;87(1036):20130719.
9. Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37(2):257–61.
10. Lin YK, Wu PK, Chen CF, Chen CM, Tsai SW, Chih-Hsueh Chen P, et al. Alveolar soft part sarcoma: Clinical presentation, treatment, and outcome in a series of 13 patients. J Chin Med Assoc 2018;81(8):735–41.
11. Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 2013;31(18):2296–302.
12. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 2017;5(1):100.
13. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol 2019;20(6):837–48.
14. Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, et al. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. Oncologist 2019;24(1):e20–9.
15. Jagodzińska-Mucha P, Świtaj T, Kozak K, Koseła-Paterczyk H, Klimczak A, Ługowska I, et al. Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma. Tumori 2017;103(3):231–5.
16. Li T, Wang L, Wang H, Zhang S, Atikan Kawuli, Zhang X, et al. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib. Invest New Drugs 2016;34(6):701–6.
17. Philip DS, Bajpai J. How I Treat Alveolar Soft Part Sarcoma? The Therapeutic Journey from Nihilism to Cautious Optimism. Indian J Med Paediatr Oncol 2024;45(1):068–73.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Insia Ali, Tasneem Dawood, Saqib Raza Khan, Khurram Minhas, Yasmin Abdul Rashid, Munira Moosajee
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
